Abiopharma

🔍 CHAN KEVIN J (Executive)

Company: WORTHINGTON ENTERPRISES, INC. (WOR)

Report Date: 2026-04-17

Detailed Transactions and Holdings:

• Holds 0 shares of Common Shares (Direct)
  Date: 2026-04-17 | Code: H | shares_owned_after: 5,806.00
• Holds 0 shares of Common Shares (Direct)
  Date: 2026-04-17 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 3,031.92 | Footnotes: F1
• Acquired 4 shares of Phantom Stock (Derivative)
  Date: 2026-04-17 | Code: A | equity_swap_involved: false | shares_owned_after: 231.02 | transaction_form_type: 4 | Footnotes: F2, F3, F3, F4

Footnotes:

• F1: The information in this report is based on a 401(k) Plan statement dated as of April 17, 2026.
• F2: The theoretical WOR common shares ("phantom stock") credited to the reporting person's account in the Worthington Industries, Inc. Amended and Restated 2005 Deferred Compensation Plan, as amended (the "Plan") track WOR common shares on a one-for-one basis.
• F3: Prior to October 1, 2014, the account balances related to the phantom stock investment option could be immediately transferred to other deemed investment options under the terms of the Plan. The Plan provides that, effective October 1, 2014 and thereafter, any amount credited in a participant's account to the phantom stock fund may not be transferred to an alternative deemed investment option under the Plan until distribution from the Plan. Distributions are made only in WOR common shares and generally commence upon leaving Worthington Enterprises, Inc. and its subsidiaries.
• F4: The amount reported includes the additional unfunded theoretical common shares (i.e., phantom stock) credited pursuant to the theoretical Worthington Enterprises, Inc. common shares deemed investment option pursuant to the dividend reinvestment feature of the 2005 NQ Plan on March 27, 2026.